Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG; Magnetic Resonance Imaging Screening Study Group. Kriege M, et al. N Engl J Med. 2004 Jul 29;351(5):427-37. doi: 10.1056/NEJMoa031759. N Engl J Med. 2004. PMID: 15282350 Free article.
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer.
Kriege M, Brekelmans CT, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Kriege M, et al. Breast Cancer Res Treat. 2007 May;102(3):357-63. doi: 10.1007/s10549-006-9341-6. Epub 2006 Oct 19. Breast Cancer Res Treat. 2007. PMID: 17051427
Hereditary breast cancer growth rates and its impact on screening policy.
Tilanus-Linthorst MM, Kriege M, Boetes C, Hop WC, Obdeijn IM, Oosterwijk JC, Peterse HL, Zonderland HM, Meijer S, Eggermont AM, de Koning HJ, Klijn JG, Brekelmans CT. Tilanus-Linthorst MM, et al. Eur J Cancer. 2005 Jul;41(11):1610-7. doi: 10.1016/j.ejca.2005.02.034. Eur J Cancer. 2005. PMID: 15978801
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer.
Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Kaas R, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, Rutgers EJ, de Koning HJ, Klijn JG. Kriege M, et al. Breast Cancer Res Treat. 2006 Nov;100(1):109-19. doi: 10.1007/s10549-006-9230-z. Epub 2006 Jun 22. Breast Cancer Res Treat. 2006. PMID: 16791481
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C. Heemskerk-Gerritsen BA, et al. Ann Surg Oncol. 2007 Dec;14(12):3335-44. doi: 10.1245/s10434-007-9449-x. Epub 2007 May 31. Ann Surg Oncol. 2007. PMID: 17541692 Free PMC article.
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG. Rijnsburger AJ, et al. J Clin Oncol. 2010 Dec 20;28(36):5265-73. doi: 10.1200/JCO.2009.27.2294. Epub 2010 Nov 15. J Clin Oncol. 2010. PMID: 21079137 Clinical Trial.
Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
Saadatmand S, Rutgers EJ, Tollenaar RA, Zonderland HM, Ausems MG, Keymeulen KB, Schlooz-Vries MS, Koppert LB, Heijnsdijk EA, Seynaeve C, Verhoef C, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MM. Saadatmand S, et al. BMC Cancer. 2012 Oct 2;12:440. doi: 10.1186/1471-2407-12-440. BMC Cancer. 2012. PMID: 23031619 Free PMC article. Clinical Trial.
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group. Saadatmand S, et al. Among authors: tilanus linthorst mma. Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17. Lancet Oncol. 2019. PMID: 31221620 Clinical Trial.
Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA, Obdeijn IM, Rutgers EJT, Saadatmand S, Mann RM, Oosterwijk JC, Tollenaar RAEM, de Roy van Zuidewijn DBW, Lobbes MBI, van 't Riet M, Hooning MJ, Ausems MGEM, Loo CE, Wesseling J, Luiten EJT, Zonderland HM, Verhoef C, Heijnsdijk EAM, Tilanus-Linthorst MMA, de Koning HJ; Familial MRI Screening (FaMRIsc) Study group. Geuzinge HA, et al. Among authors: tilanus linthorst mma. JAMA Oncol. 2020 Sep 1;6(9):1381-1389. doi: 10.1001/jamaoncol.2020.2922. JAMA Oncol. 2020. PMID: 32729887 Free PMC article.
79 results